MyBiotics Pharma LTD
MyBiotics Pharma develops live biotherapeutic products that restore microbial balance to treat gastrointestinal and other health indications. The company uses proprietary delivery and colonization technologies — MyCrobe™, SuperDonor™ and SuperDonor Select™ — to deliver single strains, defined consortia, or whole-microbiome products. Development combines proprietary culturing methods with AI and machine learning to design, optimize, and select formulations as alternatives to fecal microbiota transplantation (FMT). Lead candidates MBX-SD-201 and MBX-SD-202 target acute C. difficile infection, with additional programs in oncology, women’s health and general gut health for biopharmaceutical and supplement customers.
MyBiotics Pharma LTD
MyBiotics Pharma develops live biotherapeutic products that restore microbial balance to treat gastrointestinal and other health indications. The company uses proprietary delivery and colonization technologies — MyCrobe™, SuperDonor™ and SuperDonor Select™ — to deliver single strains, defined consortia, or whole-microbiome products. Development combines proprietary culturing methods with AI and machine learning to design, optimize, and select formulations as alternatives to fecal microbiota transplantation (FMT). Lead candidates MBX-SD-201 and MBX-SD-202 target acute C. difficile infection, with additional programs in oncology, women’s health and general gut health for biopharmaceutical and supplement customers.